TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region
TAIPEI, Taiwan and RIYADH, Saudi Arabia, March 18, 2024 (GLOBE NEWSWIRE) -- Taimed Biologics (“TaiMed”), a publicly held Taiwanese biotechnology company, signed an Exclusive License and Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a Saudi Arabia-based company operating in Middle East and North Africa region, to satisfy the unmet medical needs, under which AcedrA will register, promote and commercialize Trogarzo® (Ibalizumab-uiyk) in the MENA region.
- TAIPEI, Taiwan and RIYADH, Saudi Arabia, March 18, 2024 (GLOBE NEWSWIRE) -- Taimed Biologics (“TaiMed”), a publicly held Taiwanese biotechnology company, signed an Exclusive License and Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a Saudi Arabia-based company operating in Middle East and North Africa region, to satisfy the unmet medical needs, under which AcedrA will register, promote and commercialize Trogarzo® (Ibalizumab-uiyk) in the MENA region.
- “We are excited to broaden the reach of Trogarzo® to HIV patients in new countries.
- AcedrA, then, by a wider array of distribution activities, will be responsible for regulatory, sales, marketing, medical, and distribution in the MENA region.
- “We are committed to be a patient-centric company working closely with healthcare providers in the MENA region, and we will be pleased to partner with TaiMed strategically to improve patients' lives in the region.”